Trial Profile
Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Sponsors AstraZeneca
- 03 May 2017 New trial record